UB Paderborn / Katalog / Suche / in CDI

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

British journal of haematology, 2020-06, Vol.189 (5), p.888-903

2020

Link zum Volltext

Verfügbarkeit prüfen

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Majallat Jāmiʻat al-Malik ʻAbd al-ʻAzīz. Iqtiṣād wa-al-idārah, 2021-04, Vol.35 (2), p.1-24

Haifa Ali Al Ahmari, Haifa Ali Al Ahmari

2021

Link zum Volltext

Verfügbarkeit prüfen

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Majallat Jāmiʻat al-Malik ʻAbd al-ʻAzīz. Iqtiṣād wa-al-idārah, 2021-04, Vol.35 (2), p.1-24

Haifa Ali Al Ahmari, Haifa Ali Al Ahmari

2021

Link zum Volltext

Verfügbarkeit prüfen

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

British journal of haematology, 2013-07, Vol.162 (2), p.229-239

2013

Link zum Volltext

Verfügbarkeit prüfen

Preoperative predictors of poor laryngoscope views in pediatric population undergoing cardiac catheterization

Annals of cardiac anaesthesia, 2018-10, Vol.21 (4), p.376-381

2018

Link zum Volltext

Verfügbarkeit prüfen

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Cancer medicine (Malden, MA), 2023-09, Vol.12 (17), p.18235-18245

2023

Link zum Volltext

Verfügbarkeit prüfen

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT‐I AND ‐II TRIALS

HemaSphere, 2023-08, Vol.7 (S3), p.e85817f0-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology

Journal of patient-reported outcomes, 2022-07, Vol.6 (1), p.77-77, Article 77

2022

Link zum Volltext

Verfügbarkeit prüfen

P994: GERMLINE SINGLE‐NUCLEOTIDE VARIANTS (SNV) IN THE JAK‐STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON‐AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

HemaSphere, 2023-08, Vol.7 (S3), p.e602412a-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH‐RISK MYELODYSPLASTIC SYNDROME: A FIRST‐IN‐CLINIC PHASE 1 STUDY OF GSK3745417

HemaSphere, 2023-08, Vol.7 (S3), p.e451088e-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

British journal of haematology, 2013-07, Vol.162 (2), p.202-209

2013

Link zum Volltext

Verfügbarkeit prüfen

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

EJHaem, 2022-11, Vol.3 (4), p.1346-1351

2022

Link zum Volltext

Verfügbarkeit prüfen

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Link zum Volltext

Verfügbarkeit prüfen

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

Leukemia & lymphoma, 2012-01, Vol.53 (1), p.110-117

2012

Link zum Volltext

Verfügbarkeit prüfen

Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515 L‐positive myelofibrosis

Genes chromosomes & cancer, 2019-11, Vol.58 (11), p.747-755

2019

Link zum Volltext

Verfügbarkeit prüfen

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

HemaSphere, 2023-08, Vol.7 (S3), p.e20101d8

2023

Link zum Volltext

Verfügbarkeit prüfen

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

Leukemia, 2018-09, Vol.32 (9), p.2085-2087

2018

Link zum Volltext

Verfügbarkeit prüfen

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15

Bone marrow transplantation (Basingstoke), 2022-05, Vol.57 (5), p.824-826

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy

Preoperative predictors of poor laryngoscope views in pediatric population undergoing cardiac catheterization

Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS)

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT‐I AND ‐II TRIALS

An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

P994: GERMLINE SINGLE‐NUCLEOTIDE VARIANTS (SNV) IN THE JAK‐STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON‐AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH‐RISK MYELODYSPLASTIC SYNDROME: A FIRST‐IN‐CLINIC PHASE 1 STUDY OF GSK3745417

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

S213: BMS‐986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE‐ OR HIGH‐RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F‐ and MPLW515 L‐positive myelofibrosis

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Aktive Filter

Suchergebnisse filtern